Overview

Study of DSP-0390 in Patients With Recurrent High-Grade Glioma

Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
0
Participant gender:
All
Summary
This is a study of DSP-0390 in patients with recurrent high grade glioma.
Phase:
Early Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Sumitomo Dainippon Pharma Oncology, Inc
Criteria
Inclusion Criteria:

Estimated life expectancy >+3 months Recovery from toxic effects of prior therapy to NCI
CTCAE v5.0 Grade 1 (non-hematologic toxicities) or Grade <=2(hematologic toxicities, except
deep vein thrombosis) KPS >=70%

Adequate organ function as determined by:

- Absolute Neutrophil ≥1500/microliter (may not use G-CSF or GM CSF)

- Platelet ≥100 × 103/microliter

- Hemoglobin ≥9 g/dL (may not transfuse or use erythropoietin to obtain this Hgb level)

- Creatinine Clearance ≥ 40ml/min (Cockcroft-Gault)

- Total bilirubin ≤1.5 times ULN (or ≤ 2 times ULN for patients with known Gilbert's
syndrome)

- AST ≤ 3 times ULN

- ALT ≤ 3 times ULN

- INR, PT, PTT, or aPTT ≤1.5 x ULN Note: The use of anticoagulants is permitted as long
as the PT/(a)PTT is within therapeutic limits (according to the local institution
standard) and the patient has been on a stable anticoagulant regimen for at least 2
weeks prior to the first study treatment

If on antiepileptic drug; dose must be stable and no seizures 14 days prior to study Day 1
If on corticosteroids at baseline, dose must be stable or decreasing for at least 5 days
prior to enrollment. Dose must be ≤ 4 mg dexamethasone per day (or equivalent dose if other
corticosteroids are used). A higher stable dose of corticosteroids, if used as HRT, may be
allowed upon discussion with the Medical Monitor.

Females of childbearing potential must have a negative serum or urine pregnancy test Male
or female patients of child-producing potential must agree to use contraception or use
prevention of pregnancy measures or agreement to refrain completely from heterosexual
intercourse during the study and for 6 months (females & males) after the last dose of
study drug

Exclusion Criteria:

Prior therapy with bevacizumab or other anti-vascular endothelial growth factor (VEGF)
treatments Multifocal disease, leptomeningeal metastasis, or extracranial metastasis
Abnormal ECGs that are clinically significant, including those where QT prolongation
(QTcF>450 msec for males and >470 msec for females); and/or history of Torsade de Pointes
Left ventricular ejection fraction <40% as determined by ECHO or MUGA Known dysphagia,
short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or
gastrointestinal absorption of drugs administered orally Know active Chrohn's or other
inflammatory bowel disease History of another primary cancer within the 2 years prior to
enrollment, except for the following: nonmelamona skin cancer, cervical carcinoma in situ,
superficial bladder cancer that has been removed or curatively treated.

A known active acute or chronic infection including, but not limited to, HIV, HBV, and HCV
Pregnant or breastfeeding. [Note: Female breastfeeding patients may be enrolled if they
interrupt breastfeeding. Breastfeeding should not be resumed for at least 6 months after
the last dose of study drug.

The presence of any active retinal abnormality determined by screening tests using visual
acuity, visual field, fundoscopy, and OCT Significant cardiovascular disease, including
NYHA Class III or IV congestive heart failure, myocardial infarction, unstable angina,
poorly controlled cardiac arrhythmias, or stroke in the preceding 6 months prior to study
enrollment Uncontrolled intercurrent illness including, but not limited to, psychiatric
illness/social situations that would limit compliance with study requirements, or disorders
associated with significant immunocompromised state Major surgical procedure, surgical
resection, open biopsy, or significant traumatic injury within 4 weeks prior to study Day 1
or anticipation of need for major surgical procedure during the course of the study Minor
surgical procedures, fine needle aspirations, or core biopsies within 7 days prior to study
Day 1 Evidence of CNS hemorrhage on baseline MRI or CT scan (except for postsurgical,
asymptomatic, Gr 1 hemorrhage that has been stable at least 4 weeks for enrolled patients)
Chemotherapy or investigational anticancer therapy administered within 4 weeks (except 6
weeks for nitrosoureas and immunotherapy, or 8 weeks for an implanted nitrosoureas wafer)
prior to study Day 1 Radiotherapy within 12 weeks prior to study Day 1, unless relapse is
confirmed by tumor biopsy or new lesion outside of radiation field, or if there are 2 MRIs
(performed 8 weeks apart) confirming progressive disease Concurrent use of prohibited
medications: methylprednisolone, prednisone, carbamazepine, phenytoin, phenobarbital, and
other strong or moderate CYP3A4 inhibitors or inducers, and strong CYP2D6 inhibitors. These
should be discontinued 1 week or 5 half-lives (whichever is greater) prior to study Day 1
Concurrent treatment with Tumor Treatment Field (Optune) is not allowed. Patients must stop
Optune 1 day prior to the first dose of study drug. Any wounds from Optune must be healed
adequately prior to enrollment in this study

History of, within 6 months of study Day 1:

1. Pneumonitis or interstitial lung disease

2. Any other lung condition that in the investigators' judgement may put the patient at
an increased risk for lung toxicity (including, but not limited to, suspected
interstitial lung disease or radiation-induced lung injury)